


This article was downloaded by:

On: 27 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Organic Preparations and Procedures International

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t902189982>

PREPARATION OF 3-CHLORO-6-(TRIPHENYLMETHYLAZO) PYRIDAZINE

Carlo Farina^a; Riccardo Monguzzi^a; Mario Pinza^a

^a ISF-Institute for Biomedical Research, Milan, ITALY

To cite this Article Farina, Carlo , Monguzzi, Riccardo and Pinza, Mario(1989) 'PREPARATION OF 3-CHLORO-6-(TRIPHENYLMETHYLAZO) PYRIDAZINE', *Organic Preparations and Procedures International*, 21: 1, 125 – 128

To link to this Article: DOI: 10.1080/00304948909356355

URL: <http://dx.doi.org/10.1080/00304948909356355>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

PREPARATION OF 3-CHLORO-6-(TRIPHENYLMETHYLAZO)PYRIDAZINE


Carlo Farina, Riccardo Monguzzi and Mario Pinza*

ISF-Institute for Biomedical Research
20090 Trezzano s/N, Milan, ITALY

A number of 3-alkylamino or 3-alkoxy-6-hydrazinopyridazines possess interesting pharmacological activity and are currently undergoing clinical evaluation as peripheral vasodilators.^{1a-e} They are always prepared from 3,6-dichloropyridazine, which is commercially available or can be prepared from maleic anhydride.² While the substitution of the first chlorine atom is facile, the reactivity of the second chlorine atom is greatly diminished when the first group introduced has electron-donating properties.³ Since 3-chloro-6-hydrazinopyridazine is practically unreactive towards nucleophiles,^{4a-b} in order to obtain 3-substituted-6-hydrazinopyridazines it is necessary to introduce the hydrazino group in the amino or alkoxy substituted compound, generally by employing a great excess of hydrazine under forcing conditions.^{1a,c} This operation is not suitable for scale up; moreover, due to the high reactivity of hydrazine, by-products are often formed, especially in the case of 3-alkoxy-6-chloropyridazines which give low yields of the desired products along with corresponding amounts of 3-chloro-6-hydrazinopyridazine and 3,6-dihydrazinopyridazine.^{1e}

In order to overcome these difficulties, 3,6-dichloropyridazine was converted into 3-chloro-6-(triphenylmethylazo)pyridazine (III), in which the chlorine atom, as expected,⁵ is strongly activated toward nucleophilic

substitution, as shown by the fact that reaction with amines or alkoxides occurs smoothly. The hydrazino group is easily regenerated^{1b} by reduction of the azo⁶ followed by removal of the triphenylmethyl group by acidic treatment.⁷



This simple and very mild procedure affords high yields (up to 500 g) and eliminates the use of hazardous reagents. Moreover, for the oxidation of II to the azo derivative III, sodium hypochlorite was preferred to other oxidizing agents reported in the literature⁹ because it involves fewer problems for waste disposal in view of a scale up.

EXPERIMENTAL SECTION

Mps were taken in capillary tubes using a Büchi apparatus and are uncorrected. The IR spectra were recorded on a Perkin-Elmer 197 spectrophotometer. The NMR spectra were run with a Perkin-Elmer R12B spectrometer using TMS as an internal standard. Thin layer chromatography was performed on silica gel plates (Merck 60 FP₂₅₄), developed with cyclohexane : ethyl acetate 6:4 and visualized by UV light.

3-Chloro-6-hydrazinopyridazine (I).— To a mechanically stirred solution of 25% aqueous hydrazine (425 ml, 2.19 mol) and 30% ammonium hydroxide (750 ml, 19 mol) in water (2.4 l), 3,6-dichloropyridazine (300 g, 2.01 mol) was added, and the mixture was refluxed for 1 hr. The solution obtained was cooled to 0–5° and stirring was continued at this temperature for 3 hrs. The precipitate was collected, washed twice with water (200 ml) and dried in a vacuum oven at 40° over P_2O_5 to yield 249 g (86%) of I, mp. 140–141°, lit.^{4a} 138–139°. Nonaqueous solvent titration: 98.6%. IR (nujol mull): 3340–3000, 1630, 1600 and 830 cm^{-1} ; NMR

PREPARATION OF 3-CHLORO-6-(TRIPHENYLMETHYLAZO)PYRIDAZINE

(DMSO-d₆): δ 8.1 (bs, 1H, NHH₂), 7.30 and 7.03 (ABq J=9.3 Hz, 2H, H₄ and H₅), 4.30 (bs, 2H, NH₂).

Anal. Calcd for C₄H₅ClN₄: Cl, 24.53; N, 38.77

Found: Cl, 24.89; N, 38.91

3-Chloro-6-[2-(triphenylmethyl)hydrazino]pyridazine (II).- To a mixture of 3-chloro-6-hydrazinopyridazine (249 g, 1.72 mol) and triethylamine (240 ml, 1.72 mol) in dichloromethane (6 l), a solution of chlorotriphenylmethane (480 g, 1.72 mol) in dichloromethane (1.7 l) was added dropwise. The opalescent solution was stirred at room temperature for 1 hr. and then extracted twice with water (1.5 l). The organic phase was dried over anhydrous magnesium sulfate and evaporated under vacuum. The residue was triturated with cyclohexane (1 l) to yield 556 g (84%) of II as a cream colored solid, mp. 165-168°. Nonaqueous solvent titration: 99.7%. IR (nujol mull): 3310, 3300, 1590, 1520, 835, 755 and 695 cm⁻¹; NMR (DMSO-d₆): δ 7.40-7.17 (complex absorption, 17H, PhH, H₄ and H₅), 6.95 6.45 (bs, 2H, NHH); R_f = 0.38.

Anal. Calcd for C₂₃H₁₉ClN₄: Cl, 9.16; N, 14.48

Found: Cl, 9.59; N, 14.12

3-Chloro-6-(triphenylmethylazo)pyridazine (III).- To a solution of 3-chloro-6-[2-(triphenylmethyl)hydrazino]pyridazine (556 g, 1.437 mol) and tetrabutylammonium bromide (17.7 g, 0.055 mol) in dichloromethane (5.6 l), an 8% aqueous solution of sodium hypochlorite (4.8 kg) was slowly added over 30 minutes. Stirring was continued at room temperature for 4 hrs., then a solution of sodium metabisulfite (195 g) in water (1.7 l) was added; stirring was continued for 15 min. and the phases were separated. The aqueous layer was extracted again with dichloromethane (1.5 l), and the combined organic phases were washed with water (1.5 l), dried over anhydrous sodium sulfate and evaporated to a small volume (about 1 kg

residue). Addition of light petroleum (5 l) with vigorous stirring afforded 461 g (83%) of III as a yellow-orange solid, mp. 127-128° (with decomposition). IR (nujol mull): 1590, 1555, 740 and 690 cm^{-1} ; NMR (CDCl_3): δ 7.70 (s, 2H, H_4 and H_5), 7.30-7.15 (complex absorption, 15H, PhH); Rf = 0.57.

Anal. Calcd for $\text{C}_{23}\text{H}_{17}\text{ClN}_4$: Cl, 9.21; N, 14.55

Found: Cl, 9.62; N, 14.72

Acknowledgments.—The authors wish to thank Dr. R. Erba for spectroscopic assistance and Dr. M. Visconti for analytical support.

REFERENCES

1. a) C. Carpi, L. Dorigotti and G. Pifferi, U. S. Patent 3,925,381 (1975); C.A., 82, 4280 (1975). b) C. Farina, G. Pifferi and M. Pinza, U. S. Patent 4,575,552 (1986); C.A., 102, 113519u (1985). c) E. Bellasio, A. Campi, N. Di Mola and E. Baldoli, J. Med. Chem., 27, 1077 (1984). d) G. Steiner, J. Gries and D. Lenke, J. Med. Chem., 24, 59 (1981). e) L. Dorigotti, G. Gaviraghi, M. Pinza and G. Pifferi, U.S. Patent 4,324,788 (1982); C.A., 94, 121580 (1981).
2. R. H. Mizzoni and P. E. Spoerri, J. Am. Chem. Soc., 73, 1873 (1951).
3. D. I. Relyea, J. A. Riddell and P. O. Tawney, J. Med. Chem., 6, 807 (1963) and references cited therein.
4. a) J. A. Elvidge and J. A. Pickett, J. Chem. Soc., Perkin Trans. 1, 1483 (1972). b) S. Alazawe and J. A. Elvidge, *ibid.*, 696 (1974).
5. The activation of position 3 in compound III is due to the electron withdrawing effect of the azo group. This effect is in accordance with the positive σ_p values reported in the literature for other substituted azo groups; see C. Hansch, A. Leo, S. H. Unger, K. H. Kim, D. Nikaitani and E. J. Lien, J. Med. Chem., 16, 1207 (1973).
6. For a review on reduction of azo compounds see: B. T. Newbold in "The Chemistry of Azo, Hydrazo and Azoxy Groups" Part 2, S. Patai Ed., Interscience Pub., London, 1975, 600.
7. J. W. Barton in "Protective Groups in Organic Chemistry", J. F. W. McOmie Ed., Plenum Press, London, 1973, 65.
8. J. Druey, K. Meier, and K. Eichenberger, Helv. Chim. Acta, 39, 121 (1954).
9. G. Gaviraghi, M. Pinza and G. Pifferi, Synthesis, 608 (1981), and references cited therein.

(Received February 25, 1988; in revised form November 19, 1988)